BaP: Single Arm Phase II trial assessing the safety, compliance and activity, of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers

Project Details

Short titleBaP: Single Arm Phase II trial assessing the safety, compliance and activity, of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers
StatusFinished
Effective start/end date12/04/12 → 31/12/15

Funding

  • UHB CHARITABLE FUNDS